AzTrials
AzTrials

MicrobiotaNCT06241222

Origin of the Neonatal Gut Microbiota and Probiotic Intervention

A study testing Probiotic Blend Oral Tablet in people with Microbiota, run by Third Affiliated Hospital, Sun Yat-Sen University at 1 site in China.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This study aim to evaluate the composition and origin of the neonatal gut microbiota after birth and Probiotic intervention. Samples were obtained from a total of 30 pregnant individuals and their offspring, divided into control group and porbiotics group. Read more about this study

Who is it for?
Ages 18 to 45 years, women onlyHealthy volunteers can take part
Conditions the study is for
Microbiota
What is being tested?
Probiotic Blend Oral Tablet
Type of treatment
Pill or oral medicine
Could I receive a placebo?
No, everyone receives an active treatment
How many people
30 participants
Where
1 siteChina
Study dates
1 Jan 2018to 31 Dec 2021
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 45 years
  • Women only
  • Healthy volunteers accepted
  • Adult

Pregnant inclusive criteria were:

  1. Chinese woman who is pregnant with a single fetus;
  2. First pregnancy and term delivery.

Newborns' inclusive criteria were:

  1. Normal weight (>2500 g, <4000 g);
  2. Term Infant (>37 weeks, <42 weeks).
  3. Natural birth.

Pregnancy exclusive criteria were:

  1. Gastrointestinal disease or family history;
  2. Vaginitis before pregnancy;
  3. Antibiotic usage during pregnancy;
  4. Hypertension, Diabetes Mellitus, Hyperthyroidism, Hypothyroidism, Autoimmune Disease, or Other Endocrine and Metabolic Disease;
  5. Gestational Hypertensive Disease, Gestational Diabetes Mellitus or Other Gestational Disease;
  6. Transfusion History, Organ Transplantation History or Immunotherapy History.

Newborn's exclusive criteria were:

  1. Abnormal weight (>4000 g, <2500 g);
  2. With Congenital Diseases;3. Intrapartum Fetal Complication.

Trial locations and contacts

1 site in 1 country.

China1 site
  • Zhe Li

    Guangzhou, Guangdong, 510000

Other trials in China

About this study

This study aim to evaluate the composition and origin of the neonatal gut microbiota after birth and Probiotic intervention. Samples were obtained from a total of 30 pregnant individuals and their offspring, divided into control group and porbiotics group. Postpartum human milk and infant fecal specimens were collected for a period of 6 months. The samples were analyzed using 16S rRNA amplicon sequencing of the V3-V4 region to evaluate the microbial composition. The Shannon index, Simpson index and nonmetric multidimensional scaling were used to evaluate the diversity of the microbiota, while the co-occurrence network and LEfSe were used to evaluate the characteristics of the microbiota of pregnancies and their infants in each groups.

Read the detailed description

Study design and participants A total of 30 samples were obtained from pregnant individuals receiving antenatal care at the 1st Affiliated Hospital of Jinan University. Informed consent was obtained from pregnant women (at least 32 gestational weeks) who met the inclusion criteria. Newborns were followed until 14 days after natural delivery. Pregnant inclusive criteria were: 1. Chinese woman who is pregnant with a single fetus; 2. First pregnancy and term delivery. Newborns' inclusive criteria were: 1. Normal weight (>2500 g, <4000 g); 2. Term Infant (>37 weeks, <42 weeks). 3. Natural birth. Pregnanct exclusive criteria were: 1. Gastrointestinal disease or family history; 2. Vaginitis before pregnancy; 3. Antibiotic usage during pregnancy; 4. Hypertension, Diabetes Mellitus, Hyperthyroidism, Hypothyroidism, Autoimmune Disease, or Other Endocrine and Metabolic Disease; 5. Gestational Hypertensive Disease, Gestational Diabetes Mellitus or Other Gestational Disease; 6. Transfusion History, Organ Transplantation History or Immunotherapy History. Newborn's exclusive criteria were: 1. Abnormal weight (>4000 g, <2500 g); 2. With Congenital Diseases;3. Intrapartum Fetal Complication.

Probiotic management In the investigators' study, fourteen pregnant women were randomly assigned to the probiotic group, and the rest were assigned to the control group. After enrollment, pregnant women in the probiotic group received a combination of living Bifidobacterium longum (5 ∗ 106 CFU), Lactobacillus delbrueckii bulgaricus (5 ∗ 105 CFU) and Streptococcus thermophilus (5 ∗ 105 CFU) tablets produced by Neimengu Shuangqi Pharmaceutical Co., Ltd. Pregnant individuals in the probiotic group were administered two tablets twice a day (2 g/d) until natural delivery, and those in the control group took no pills.

Fecal, vaginal secretion, placental, and meconium collection Fecal collection Feces from pregnant patients were collected twice-between weeks 32 and 34 and before natural labor. Feces collected at weeks 32-34 were collected internally, thereby avoiding contamination with foreign material. The feces were stored in a domestic refrigerator and transferred to the laboratory freezer at -80 ºC for 24 hours. Feces collected before labor were obtained in the hospital and transferred to the laboratory freezer within 30 min of collection.

Vaginal secretion collection Vaginal secretions were collected twice between weeks 32 and 34 and before natural labor. The pregnant woman was asked to not engage in sexual behavior, clean the vulva, clean the vagina, or use vaginal medicine within 48 hours before sample collection. Vaginal secretions before natural labor were collected before membrane rupture occurred. The samples were transferred to the laboratory freezer within 30 min of collection, thereby avoiding contamination by foreign material.

Placenta collection Placenta samples ranging from the entire umbilical cord to 3 cm were collected by stripping the amniotic membrane after natural birth. The blood was rinsed with sterile saline. Four to six pieces of placenta were sampled from the fetal surface. Each piece had a volume of approximately 1 cm3. The placenta sample was transferred to the laboratory freezer within 30 min of collection.

Meconium collection Meconium was collected three times on the 1st day, the 3rd day, and the 14th day after natural delivery On the 1st day and 3rd day, meconium was collected internally, thereby avoiding contamination with foreign material in the hospital, and was transferred to the laboratory freezer within 30 min of collection. On the 14th day, meconium was collected, stored in a domestic refrigerator, and then transferred to a laboratory freezer within 24 hours of collection.

When infants were 6 months old, postpartum milk was collected by two full-time members of the research group. The human milk samples were collected according to a standardized protocol. Before collecting the samples, the nursing mothers were required to clean the nipple and areola with soap and water. A total sample volume of 6 ml was collected in a sterile tube. Additionally, infant fecal samples were collected at the 6th month postpartum. After collection, the samples were stored with dry ice for transportation to the laboratory immediately. Upon arrival at the laboratory, the samples were briefly thawed to allow for accurate aliquoting. Each sample was then divided equally into smaller frozen storage tubes. The divided samples were promptly refrozen and stored in a freezer at -80°C within 4 hours after collection. This process ensured that the samples were handled with minimal temperature fluctuations to preserve their integrity.

Fecal samples from the infants were collected internally in sterile and dedicated collecting boxes, thereby avoiding any contamination with foreign material. These samples were stored in a domestic freezer (-20°C) and transferred to a laboratory freezer at -80°C within 24 hours using a cryogenic transport container to ensure they remained frozen during the transfer.

Conditions
Microbiota
Being tested
Probiotic Blend Oral Tablet

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Probiotic Blend Oral TabletDrug

    In our study, fourteen pregnant women were randomly assigned to the probiotic group, and the rest were assigned to the control group. After enrollment, pregnant women in the probiotic group received a combination of living Bifidobacterium longum (5 ∗ 106 CFU), Lactobacillus delbrueckii bulgaricus (5 ∗ 105 CFU) and Streptococcus thermophilus (5 ∗ 105 CFU) tablets produced by Neimengu Shuangqi Pharmaceutical Co., Ltd. Pregnant individuals in the probiotic group were administered two tablets twice a day (2 g/d) until natural delivery

Study groups in NCT06241222
Study groupRoleWhat they receive
control groupNo interventionpregnancies in control group need no intervention.
probiotics groupExperimentalpregnancies in probiotics group need probiotics management
Receives: Drug: Probiotic Blend Oral Tablet

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. 16S rRNA amplicon sequencing of the V4 region

    Difference analysis of each group was performed. All the measurement data are presented as the mean ± standard error. Assessments of Operational Taxonomic Units differences in the probiotic group and control group were performed using independent sample t tests, and P < 0.05 was considered to indicate statistical significance. Other outcomes were analyzed using multiple linear regression. All data were analyzed using SPSS 23.0 statistical software (SPSS, Inc., Chicago, IL, USA).

    Measured: 12 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted5 Feb 2024
  2. Study start1 Jan 2018
  3. Primary completion31 Dec 2021
  4. Study completion31 Dec 2021

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Health services research
Allocation
Randomised
Intervention model
Single group
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
30 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06241222
Sponsor's protocol ID
[2019]no.11EthicsCommittee
Status last verified
Jul 2024
First submitted
17 Jan 2024
Last updated
9 Sep 2025
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Yang P, Li Z, Tye KD, Chen Y, Lu T, He Z, Zhou J, Xiao X. Effects of an orally supplemented probiotic on the autophagy protein LC3 and Beclin1 in placentas undergoing spontaneous delivery during normal pregnancy. BMC Pregnancy Childbirth. 2020 Apr 15;20(1):216. doi: 10.1186/s12884-020-02905-z.

    PubMed 32295534
  • Huang T, Li Z, Tye KD, Chan SN, Tang X, Luo H, Wang D, Zhou J, Duan X, Xiao X. Probiotic supplementation during pregnancy alters gut microbial networks of pregnant women and infants. Front Microbiol. 2022 Dec 1;13:1042846. doi: 10.3389/fmicb.2022.1042846. eCollection 2022.

    PubMed 36532501
  • Chen Y, Li Z, Tye KD, Luo H, Tang X, Liao Y, Wang D, Zhou J, Yang P, Li Y, Su Y, Xiao X. Probiotic Supplementation During Human Pregnancy Affects the Gut Microbiota and Immune Status. Front Cell Infect Microbiol. 2019 Jul 16;9:254. doi: 10.3389/fcimb.2019.00254. eCollection 2019.

    PubMed 31380297
  • Meng L, Fan G, Xie H, Tye KD, Xia L, Luo H, Tang X, Huang T, Lin J, Ma G, Xiao X, Li Z. Maternal-to-neonatal microbial transmission and impact of prenatal probiotics on neonatal gut development. J Transl Med. 2025 Oct 30;23(1):1198. doi: 10.1186/s12967-025-07293-6.

    PubMed 41168767
  • Ma G, Li Y, Tye KD, Huang T, Tang X, Luo H, Wang D, Zhou J, Li Z, Xiao X. The effect of oral probiotics in the last trimester on the human milk and infant gut microbiotas at six months postpartum: A randomized controlled trial. Heliyon. 2024 Aug 30;10(17):e37157. doi: 10.1016/j.heliyon.2024.e37157. eCollection 2024 Sep 15.

    PubMed 39286230

Questions about this trial

What is this clinical trial studying?

A study testing Probiotic Blend Oral Tablet in people with Microbiota, run by Third Affiliated Hospital, Sun Yat-Sen University at 1 site in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 9 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

16S rRNA amplicon sequencing of the V4 region (time frame: 12 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06241222, which also lists 5 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Sep 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in